Ann: Confirmation Sofpironium Bromide NDA Formally Under Review, page-57

Couldn't agree more that our company have already known about the positive outcomes and most likely will be approved by FDA.

Based on the Research Report by Euroz Hartleys – 8 December 2022 ( Read the full report), Analyst Seth Lizee classified the Company as a ‘Speculative Buy, $0.27 Price Target.
Cheapest NDA Filing on ASX? In our analysis,
* Whilst companies are in varying positions (different disease areas, some with licensing agreements already in place, ex. US approvals, and/or multiple other products)– indicatively, the market has paid ~A$110-600 million on FDA NDA filing day (pre- FDAapproval) and ~A$250-2,500 million upon FDA approval.
*BOT trades well below every single comp listed above with a fully diluted $77 million market cap, which per our analysis would make it one of the cheapest ASX companies seeking FDA approval on their first drug